Core Insights - Chronic rhinosinusitis with nasal polyps (CRSwNP) affects over 40 million patients in China, with more than 50% unable to effectively control symptoms under current treatment systems [1][2] - The study published in JAMA demonstrates the efficacy and safety of the domestic biologic drug, Supacib, in treating severe uncontrolled CRSwNP [1][3] Group 1: Study Overview - The CROWNS-2 clinical trial is a nationwide, multicenter, randomized, double-blind, placebo-controlled phase III study aimed at evaluating the efficacy and safety of Supacib in a large sample of CRSwNP patients [2] - The trial recruited 180 patients from 51 centers across China between August 2022 and April 2023, focusing on those with severe symptoms unresponsive to standard treatment [2] Group 2: Results and Implications - Results indicate that treatment with Supacib for 24 weeks significantly reduces nasal polyp volume, alleviates nasal congestion and loss of smell, and greatly improves quality of life [3] - After 52 weeks of maintenance treatment, nearly 90% of patients achieved at least a 50% reduction in nasal polyp volume, marking a significant breakthrough in the treatment of CRSwNP in China [3]